Selling pressure pushes Moderna lower in today trading

Traders Union
All News
Financial News
Moderna slides 6.58% today to $49.38

Highlights

The EMA’s CHMP recommended marketing authorization for Moderna’s mCOMBRIAX, a combined influenza and COVID-19 vaccine, following positive phase 3 data in around 8,000 adults aged 50+.
BioNTech has filed a new patent lawsuit against Moderna over mRNA COVID-19 vaccine technology, while the US FDA recently declined review of Moderna’s standalone flu vaccine due to trial design concerns.
Moderna trades at $49.38 above all key moving averages, with technical support at $45.77 and resistance at $51–$52; momentum remains bullish despite overbought signals and high volatility.

Pipeline progress offset by regulatory setbacks and legal dispute

The European Medicines Agency’s CHMP recommended marketing authorization for Moderna's mCOMBRIAX (mRNA-1083), a combined influenza and COVID-19 vaccine for adults aged 50 and older, following successful phase 3 trial results in around 8,000 participants. The US FDA has recently refused to review Moderna’s standalone flu vaccine mRNA-1010 due to trial design concerns. In addition, BioNTech initiated a new patent lawsuit against Moderna regarding mRNA COVID-19 vaccine technology, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Moderna’s price action as vulnerable amid today’s sharp selloff. He points out that although bullish above key moving averages, overbought signals cluster across oscillators, suggesting near-term exhaustion. Kharitonov notes regulatory setbacks, like the FDA’s refusal to review mRNA-1010 and the new BioNTech lawsuit, add to downside risks and may erode investor sentiment. He warns that the recent move was marked by high volatility and strong selling pressure, with support at $45.77 now critical. "Moderna’s structure appears bullish, but these technical and fundamental headwinds mean traders should be cautious about chasing further gains at these levels," he says.

Viktoras Karapetjanc, expert at Traders Union, remains confident in Moderna’s overall market position. He highlights the positive momentum following the European CHMP’s recommendation for mCOMBRIAX, reinforcing market optimism. Karapetjanc emphasizes that the stock stays above key supports, and a high probability of price increase signals further opportunity. He sees the broader trend as intact despite short-term volatility, pointing to bullish potential if resistance levels break. "I see Moderna poised for new gains as regulatory milestones and strong technicals continue to offer attractive setups for growth," he states.

Bull trend persists as momentum diverges with overbought signals

Moderna’s current price of $49.38 is trading above key moving averages: the MA-20 at $45.83, MA-50 at $41.10, and MA-200 at $30.56, reflecting a confidently bullish trend across short, medium, and long-term timeframes. The closest dynamic support is indicated by the Ichimoku Kijun level at $45.77, with the MA-50 at $41.10 serving as additional intermediate support should the price decline.

Momentum signals on the daily chart remain positive with both the MACD and ADX continuing to support buying pressure, though several oscillators present overbought warnings. The daily RSI is elevated at 71.52, while Stoch RSI and CCI both signal overbought conditions, and Bull/Bear Power (BBP) is deep in overbought territory, reinforcing that buyers have dominated recent sessions. However, the Awesome Oscillator is currently neutral, not amplifying the prevailing trend. Intraday, the stock opened lower at $50.11 versus yesterday’s close of $52.85, leaving a meaningful downside gap and now trades near today’s low after dropping 6.58%. Volatility is high, with the move marked by sharp post-open selling pressure. Divergence is evident as momentum remains strong, yet several oscillators and intraday behavior warn of near-term exhaustion and possible pullback.

Previously it was reported that Moderna Inc. is trading firmly above its key moving averages, indicating sustained bullish momentum across multiple time frames, with positive MACD and ADX readings supporting the uptrend despite the stock facing ongoing selling pressure. However, several momentum oscillators including Stoch RSI and CCI are now at overbought levels near immediate resistance, suggesting a heightened risk of near-term consolidation or pullback as the stock approaches psychological thresholds.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.